Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
46 hedge funds and large institutions have $63.4M invested in Agile Therapeutics in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 5 closing their positions.
3,900% more call options, than puts
Call options by funds: $40K | Put options by funds: $1K
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
2% more funds holding
Funds holding: 45 → 46 (+1)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
3% less capital invested
Capital invested by funds: $65.5M → $63.4M (-$2.06M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$1.93M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$1.61M |
| 3 |
PA
Perceptive Advisors
New York
|
+$496K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$304K |
| 5 |
Renaissance Technologies
New York
|
+$278K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$964K |
| 2 |
RA
Royce & Associates
New York
|
-$793K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$483K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$469K |
| 5 |
Barclays
London,
United Kingdom
|
-$205K |
AGRX Hedge Fund Activity: Q1 2018 in Review
46 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q1 2018, worth a combined $63.4M — down 3.1% from $65.5M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AGRX positions and 5 closed out — a net gain of 1 holder — while 13 added to existing stakes and 13 trimmed.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $1.93M. The largest seller was Broadfin Capital, exiting entirely with an estimated $964K sold.
- 46 institutional investors held Agile Therapeutics (AGRX) as of Q1 2018, up from 45 in Q4 2017.
- Funds reported $63.4M of Agile Therapeutics stock for Q1 2018, down 3.1% quarter-over-quarter.
- 6 funds opened new Agile Therapeutics positions in Q1 2018 and 5 closed out, a net change of +1 holder.
- The largest Agile Therapeutics buyer in Q1 2018 was J. Goldman & Co, an estimated $1.93M added.
- The largest Agile Therapeutics seller in Q1 2018 was Broadfin Capital, an estimated $964K sold.
Based on aggregated 13F filings for Q1 2018.